Search

Your search keyword '"Derman, Jonathan"' showing total 11 results
Start Over Author "Derman, Jonathan"
11 results on '"Derman, Jonathan"'

2. Evaluation of the Idylla system to detect the EGFRT790M mutation using extracted DNA

Author

Bocciarelli, Claire, Cohen, Justine, Pelletier, Romain, Tran van Nhieu, Jeanne, Derman, Jonathan, Favre, Loetitia, Bourgogne, Anaïs, Monnet, Isabelle, Chouaid, Christos, Pujals, Anaïs, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CHU Henri Mondor, Université Paris-Est Créteil Val-de-Marne - Faculté de médecine (UPEC Médecine), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CHI Créteil, and CCSD, Accord Elsevier

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], Extracted DNA, Next-generation sequencing, Lung cancer, Idylla, EGFRT790M
Abstract

International audience; Introduction: During the last few years, detection of epidermal growth-factor-receptor (EGFR)-activating mutations has become a routine part of clinical practice because of their importance in choosing the optimal treatment strategy for non-small-cell lung cancers (NSCLCs). The emergence of third-generation EGFR-tyrosine-kinase inhibitors required the implementation of sensitive methods to detect the subclonal EGFRT790M mutation. Clinical implications make it essential to rapidly search for the T790M mutation, which is a real challenge for laboratories. The aim of this study was to compare performances of next-generation sequencing (NGS), one of the most frequently used molecular biology methods, and Idylla EGFR-Mutation Assay (henceforth Idylla), a fully automated real-time polymerase chain reaction (PCR) that is increasingly used in pathology laboratories, to detect the EGFRT790M mutation using DNA.Methods: This retrospective study used 47 DNA samples extracted from NSCLC biopsies that previous NGS identified as: 29 harboring EGFR and T790M resistance mutations, 11 EGFR-activating mutation without T790 M and 7 wild-type EGFR. EGFRT790M limit-of-detection (LOD) experiments used a commercial DNA known to harbor that mutation.Results: Idylla detected primary EGFR-activating mutations and the T790 M mutation in 97.5 % and 65.5 % of the cases, respectively. The results of this retrospective analysis and LOD experiments showed that the Idylla should only be used to detect EGFR mutations in samples with > 25 ng of DNA and > 10 % tumor cells.Conclusions: Idylla was able to rapidly detect EGFR-activating mutations but detecting subclone mutations, like T790M, with < 25 ng of good-quality DNA or < 10 % tumor cells (variant allele frequency below the assay's validated LOD) was not always reliable.

Published
2020

3. Early Hepatic Lesions Display Immature Tertiary Lymphoid Structures and Show Elevated Expression of Immune Inhibitory and Immunosuppressive Molecules

Author

Meylan, Maxime, primary, Petitprez, Florent, additional, Lacroix, Laetitia, additional, Di Tommaso, Luca, additional, Roncalli, Massimo, additional, Bougoüin, Antoine, additional, Laurent, Alexis, additional, Amaddeo, Giuliana, additional, Sommacale, Daniele, additional, Regnault, Hélène, additional, Derman, Jonathan, additional, Charpy, Cécile, additional, Lafdil, Fouad, additional, Pawlotsky, Jean-Michel, additional, Sautès-Fridman, Catherine, additional, Fridman, Wolf H., additional, and Calderaro, Julien, additional

Published
2020
Full Text
View/download PDF

5. RBM10‐TFE3 fusions: A FISH‐concealed anomaly in adult renal cell carcinomas displaying a variety of morphological and genomic features: Comprehensive study of six novel cases.

Author

Di Mauro, Ilaria, Dadone‐Montaudie, Bérengère, Sibony, Mathilde, Ambrosetti, Damien, Molinie, Vincent, Decaussin‐Petrucci, Myriam, Bland, Vincent, Arbaud, Claire, Cenciu, Béatrice, Arbib, François, Just, Pierre‐Alexandre, Derman, Jonathan, Rioux‐Leclercq, Nathalie, and Pedeutour, Florence

Published
2021
Full Text
View/download PDF

7. Macrotrabecular‐massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance

Author

Ziol, Marianne, primary, Poté, Nicolas, additional, Amaddeo, Giuliana, additional, Laurent, Alexis, additional, Nault, Jean‐Charles, additional, Oberti, Frédéric, additional, Costentin, Charlotte, additional, Michalak, Sophie, additional, Bouattour, Mohamed, additional, Francoz, Claire, additional, Pageaux, Georges Philippe, additional, Ramos, Jeanne, additional, Decaens, Thomas, additional, Luciani, Alain, additional, Guiu, Boris, additional, Vilgrain, Valérie, additional, Aubé, Christophe, additional, Derman, Jonathan, additional, Charpy, Cécile, additional, Zucman‐Rossi, Jessica, additional, Barget, Nathalie, additional, Seror, Olivier, additional, Ganne‐Carrié, Nathalie, additional, Paradis, Valérie, additional, and Calderaro, Julien, additional

Published
2018
Full Text
View/download PDF

8. The True Ablation Effect of Holmium YAG Laser on Soft Tissue

Author

Emiliani, Esteban, primary, Talso, Michele, additional, Haddad, Mattieu, additional, Pouliquen, Christelle, additional, Derman, Jonathan, additional, Côté, Jean-François, additional, Doizi, Steeve, additional, Millán, Felix, additional, Berthe, Laurent, additional, Audouin, Marie, additional, and Traxer, Olivier, additional

Published
2018
Full Text
View/download PDF

9. Recul à 10 ans des patients opérés pour un cancer de prostate Gleason 6 (ISUP1)

Author

Bihan, Elodie Le, Derman, Jonathan, Salomon, Laurent, Taille, Alexandre De La, Irani, Jacques, and Lebacle, Cédric

Abstract

OBJECTIF : Le Cancer prostatique (CaP) classé Gleason 6 (G6) ISUP 1 est considéré de bon pronostic. L’objectif de cette étude était d’évaluer dans une population traitée par prostatectomie radicale (PR) pour un CaP G6 l’association avec des stades extra-prostatiques et la survie.

Published
2021
Full Text
View/download PDF

11. Evaluation of the Idylla system to detect the EGFR T790M mutation using extracted DNA.

Author

Bocciarelli C, Cohen J, Pelletier R, Tran Van Nhieu J, Derman J, Favre L, Bourgogne A, Monnet I, Chouaid C, and Pujals A

Subjects
ErbB Receptors genetics, Humans, Lung Neoplasms genetics, Lung Neoplasms pathology, Mutation genetics, Carcinoma, Non-Small-Cell Lung genetics, DNA genetics, Drug Resistance, Neoplasm genetics
Abstract

Introduction: During the last few years, detection of epidermal growth-factor-receptor (EGFR)-activating mutations has become a routine part of clinical practice because of their importance in choosing the optimal treatment strategy for non-small-cell lung cancers (NSCLCs). The emergence of third-generation EGFR-tyrosine-kinase inhibitors required the implementation of sensitive methods to detect the subclonal EGFR T790M mutation. Clinical implications make it essential to rapidly search for the T790M mutation, which is a real challenge for laboratories. The aim of this study was to compare performances of next-generation sequencing (NGS), one of the most frequently used molecular biology methods, and Idylla EGFR-Mutation Assay (henceforth Idylla), a fully automated real-time polymerase chain reaction (PCR) that is increasingly used in pathology laboratories, to detect the EGFR T790M mutation using DNA., Methods: This retrospective study used 47 DNA samples extracted from NSCLC biopsies that previous NGS identified as: 29 harboring EGFR and T790M resistance mutations, 11 EGFR-activating mutation without T790 M and 7 wild-type EGFR. EGFR T790M limit-of-detection (LOD) experiments used a commercial DNA known to harbor that mutation., Results: Idylla detected primary EGFR-activating mutations and the T790 M mutation in 97.5 % and 65.5 % of the cases, respectively. The results of this retrospective analysis and LOD experiments showed that the Idylla should only be used to detect EGFR mutations in samples with > 25 ng of DNA and > 10 % tumor cells., Conclusions: Idylla was able to rapidly detect EGFR-activating mutations but detecting subclone mutations, like T790M, with < 25 ng of good-quality DNA or < 10 % tumor cells (variant allele frequency below the assay's validated LOD) was not always reliable., (Copyright © 2019 Elsevier GmbH. All rights reserved.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results